Caribou Biosciences (NASDAQ:CRBU) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Caribou Biosciences (NASDAQ:CRBU) from a hold rating to a sell rating in a research report released on Saturday morning.

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Caribou Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Caribou Biosciences Trading Up 0.9%

Shares of CRBU opened at $1.12 on Friday. The stock has a market cap of $104.17 million, a PE ratio of -0.68 and a beta of 2.44. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.00. The stock has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $1.25.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, sell-side analysts forecast that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

A number of large investors have recently bought and sold shares of the business. Centric Wealth Management acquired a new position in Caribou Biosciences in the fourth quarter worth $27,000. Cerity Partners LLC raised its holdings in shares of Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock valued at $37,000 after buying an additional 25,271 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after buying an additional 21,416 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after acquiring an additional 9,148 shares during the last quarter. Finally, Diametric Capital LP acquired a new stake in Caribou Biosciences in the 4th quarter valued at about $42,000. 77.51% of the stock is currently owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.